Neonatal urticaria due to prostaglandin E1

Area of Science:

• Neonatal dermatology
• Pediatric cardiology
• Pharmacology

Background:

• Prostaglandin E1 is a critical vasodilator used in managing cyanotic congenital heart disease.
• Common side effects include cutaneous flushing and peripheral edema.
• Dermatologic literature lacks comprehensive documentation of prostaglandin E1's cutaneous effects.

Observation:

• A neonate diagnosed with transposition of the great vessels was treated with prostaglandin E1.
• The infant developed a distinct urticarial rash during the course of treatment.
• This observation was made in the context of standard prostaglandin E1 administration.

Findings:

• Urticaria emerged as a previously undescribed cutaneous side effect of prostaglandin E1 therapy.
• The case highlights a potential hypersensitivity or idiosyncratic reaction to prostaglandin E1.
• This finding expands the known spectrum of adverse cutaneous events associated with prostaglandin E1.

Implications:

• Clinicians should be aware of urticaria as a potential adverse effect of prostaglandin E1.
• Further investigation into prostaglandin E1's dermatologic side effect profile is warranted.
• This case may prompt a review of monitoring protocols for patients receiving prostaglandin E1.